3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial. (September 2015) - Hassan, R.; Thomas, A.; Patel, M.; Nemunaitis, J.; Bennouna, J.; Powderly, J.; Taylor, M.; Cuillerot, J.M.; Heydebreck, A. Von; Gulley, J.L.